Celcuity (NASDAQ:CELC) Reaches New 1-Year High – Here’s What Happened

Celcuity, Inc. (NASDAQ:CELC)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $120.32 and last traded at $115.5760, with a volume of 155148 shares. The stock had previously closed at $114.01.

Wall Street Analyst Weigh In

CELC has been the topic of several research reports. Wells Fargo & Company assumed coverage on shares of Celcuity in a research note on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $94.00 price objective (up previously from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Craig Hallum boosted their price target on shares of Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Finally, Needham & Company LLC set a $95.00 target price on Celcuity in a report on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Celcuity presently has a consensus rating of “Moderate Buy” and an average price target of $105.25.

Celcuity Trading Up 3.3%

The firm has a market capitalization of $5.45 billion, a PE ratio of -31.89 and a beta of 0.25. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The business’s fifty day moving average price is $102.72 and its 200 day moving average price is $69.75.

Celcuity (NASDAQ:CELC) last released its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.13. As a group, analysts expect that Celcuity, Inc. will post -2.62 EPS for the current fiscal year.

Insider Transactions at Celcuity

In other news, Director Richard E. Buller sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $105.69, for a total transaction of $317,070.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at approximately $714,464.40. This trade represents a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Celcuity

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Celcuity during the third quarter valued at approximately $27,000. US Bancorp DE grew its stake in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after buying an additional 1,167 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Celcuity by 211.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after acquiring an additional 3,766 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in Celcuity in the third quarter worth $79,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.